Drug Profile
Pegfilgrastim biosimilar - Intas Biopharmaceuticals
Alternative Names: INTP 5; Lapelga; Neupeg; Pegasta; Pegylated Apo-Filgrastim; Pelgraz; Recombinant pegylated granulocyte colony stimulating factor - Intas BiopharmaceuticalsLatest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Intas Biopharmaceuticals
- Developer Apotex; Intas Biopharmaceuticals; Intas Pharmaceuticals
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
- Phase III Rhabdomyosarcoma